Abstract:Objective: The aim of this study was to compare the efficacy and safety of nebulized arformoterol 15 microg/2 mL twice daily (ARF15 BID) and 30 microg/4 mL once daily (ARF30 QD) in subjects with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: In this single-dose, multicenter, randomized, modified-blind, 2-way crossover study, subjects aged > or =45 years with moderate to severe COPD, a forced expiratory volume in 1 second (FEV(1)) > or =0.7 L, and < or =65% predicted FEV1, and a FEV(1):forced vital capacity ratio < or =70% were randomly assigned to receive single-day treatment with ARF15 BID or ARF30 QD in random order, separated by a 5 +/- 2-day washout period. The primary efficacy end point was time-normalized AUC of FEV(1) from baseline (hour 0) to 24 hours (FEV(1)AUC(0-24)). Secondary efficacy end points were time-normalized AUC of FEV(1) from baseline to 12 hours (FEV(1)AUC(0-12)) and from 12 to 24 hours (FEV(1)AUC(12-24)), and FEV(1) at 24 hours after administration of the morning dose (trough FEV(1)). Equivalence of the 2 therapies was assessed by comparing the 90% CI value for the difference of the least squares mean (LSM) to a study-specific predefined equivalence range for change in FEV(1)AUC(0-24) of -0.07 to 0.07 L. Results: A total of 33 subjects were enrolled (20 men, 13 women; mean [SD] age, 64.5 [8.8] years; 15 subjects received ARF15 BID first; 18 received ARF30 QD first). ARF15 BID and ARF30 QD were associated with similar improvements from baseline in (FEV(1)AUC(0-24), LSM 0.15 and 0.16 L, respectively; Delta, 0.01 L; 90% CI, -0.02 to 0.04) and trough FEV(1) (LSM, 0.15 and 0.12 L, respectively; Delta, -0.03 L; 90% CI, -0.09 to 0.03). FEV(1)AUC(0-12) was improved more with ARF30 QD than ARF15 BID (Delta, 0.06 L; 90% CI, 0.04 to 0.09), and FEV(1)AUC(12-24) was improved more with ARF15 BID than ARF30 Qd (Delta, -0.04 L; 90% CI, -0.08 to 0.01). The 90% CI for FEV(1)AUC(0-24) for the treatment difference between ARF15 BID and ARF30 QD was within the prespecified range of -0.07 to 0.07 L, indicating that both treatments resulted in equivalent FEV(1)AUC(0-24) values. Conclusions: In these subjects with moderate to severe COPD, single-day administrations of ARF15 BID or ARF30 QD were associated with FEV(1) responses over a period of 24 hours that were considered equivalent per the protocol definition employed in the present study. FEV1 improvement over 12 hours was greater for ARF30 QD after the morning dose and for ARF15 BID after the evening dose. ClinicalTrials.gov Identifier: NCT00571428.

Efficacy of formoterol in asthma: a multicenter, double-blind and randomized study

Efficacy and Safety of Budesonide/formoterol Single Inhaler Therapy Versus Budesonide Inhaler Plus Formoterol Inhaler in Asthma Patients

Multicenter Randomized Controlled Clinical Trial of Mabuterol Hydrochloride Tablets Versus Procaterol Hydrochloride in the Treatment of Bronchial Asthma

A Three-Month Non-Interventional Study of Asthma Treatment with Budesonide/Formoterol

The Efficacy of Budesonide-formoterol in Patients with Acute Attacks of Mild-to-moderate Bronchial Asthma: An Observational Study

Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study

Comparison of the Effects of Salmeterol/fluticasone Versus Fluticasone over 1-Year on Small Airway Functions in Asthmatics

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.

Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma

Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study

Budesonide/Formoterol Maintenance and Reliever Therapy in Chinese Patients with Asthma

Clinical Efficacy of Salbutamol Sulfate Sustained-Release Capsules in the Treatment of Bronchial Asthma in Adults

Efficacy and safety of pemirolast potassium in comparison with tranilast for bronchial asthma and allergic rhinitis:a multicenter,randomized,double-blind,double-dummy,parallel-group trial

Clinical research on bambuterol solution and tablet

On Epistemic Logic and Logical Omniscience

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

Comparison of the efficacy of salbutamol sustained release capsule and bambuterol tablet in asthma

Early Observations of the Afterglow of GRB 000301c

Treatment efficacy evaluation of standardized management for children with asthma

Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis